Hypergendered Logic Source

Hypergendered Logic — Page 281

HGL Source Framework · Page 281 of 293 · Source: Hypergendered Logic

C2 > C1 > 0 => T_i(C2) < T_i(C1), other relevant variables held fixed. 
R2 > R1 => J_i(R2) >= J_i(R1), with strict increase throughout the receptor-responsive range. 
This yields an Orthogonal Endocrine-Control Principle: changing amount alone does not constitutively 
change jump magnitude, and changing receptor sensitivity alone does not constitutively change the waiting 
interval. A future interaction law may couple them, but no such coupling is silently assumed. 
426. General receptor-gating and hormone-stop rules 
The medication architecture includes complete receptor insensitivity and complete hormone suppression. To 
give those concepts exact meaning, HGL adopts a general receptor-gating clarification for all ten named 
Archstage hormones: zero effective receptor sensitivity blocks the hormone-mediated coordinate jump, 
regardless of hormone amount. Likewise, zero effective hormone exposure produces no hormone-driven 
jump event regardless of receptor sensitivity, unless another nonhormonal causal pathway is explicitly 
supplied. 
R_i=0 => J_i=0. 
C_i=0 => T_i=infinity / no hormone-driven jump event. 
These are causal-control rules, not claims that the bearer loses previously attained Archstage. They create 
stagnation of the relevant hormone-driven coordinate channel, not regression. 
427. Female Archstage endocrine map 
Raeyol, named after Rhayhara, is the ovarian Archwomanhood Hyperstage hormone. Raeyol receptor 
sensitivity controls Hyperstage jump magnitude. Raeyol amount controls the time interval to the jump. Raeyol 
receptors have no upper sensitivity limit under the fictional HGL scale. At zero Raeyol receptor sensitivity 
there is absolutely no Raeyol-driven Hyperstage increase. 
Alygorin is the ovarian Archwomanhood Stage hormone. Alygorin receptor sensitivity controls Stage jump 
magnitude; Alygorin amount controls the time interval to that Stage jump. Alygorin receptor sensitivity is 
bounded and cannot generate a Stage jump beyond the Hyperomega bound. 
Operalin is the ovarian Archwomanhood Substage hormone. Operalin receptor sensitivity controls Substage 
jump magnitude; Operalin amount controls the interval. Its effective receptor sensitivity is bounded by the 
Substage Hyperomega jump ceiling. 
Zilanin is the ovarian Archwomanhood Substage^2 hormone. Zilanin receptor sensitivity controls Substage^2 
jump magnitude; Zilanin amount controls the interval. Its effective jump is bounded by Hyperomega. 
Tolurarin is the ovarian Archwomanhood Substage^3 hormone. Tolurarin receptor sensitivity controls 
Substage^3 jump magnitude; Tolurarin amount controls the interval. Its effective jump is bounded by 
Hyperomega. 
Female controller vector: E_F = 
((C_Rae,R_Rae),(C_Aly,R_Aly),(C_Ope,R_Ope),(C_Zil,R_Zil),(C_Tol,R_Tol)). 
428. Raeyol unbounded-Hyperstage sensitivity semantics 
Raeyol receptor sensitivity must not be silently modeled as an ordinary real-valued variable with a fixed 
maximum, because the user-defined biology assigns it no upper limit and allows it to control an unbounded 
Hyperstage jump scale. HGL therefore treats the effective Raeyol-sensitivity domain as an unbounded 
ordered HGL sensitivity class rather than presupposing R_Rae is a conventional percentage or bounded real 
number. 
J_Rae(0)=0.

Source Canon: Verbatim mathematical and modal logic. Interactive navigation and operator lookups available at /#hgl-part:281.